Personalized Cancer Vaccine Demonstrates Significant Survival Benefit
A new mRNA therapy designed to target individual tumors has proven effective in a major trial.
By Tunde Bailey ·
A personalized mRNA vaccine targeting melanoma has reduced the risk of death or recurrence by 42 percent compared to standard treatment, according to results announced today. Pharmaceutical partners Merck and Moderna released the data, indicating the therapy has met its primary goal in a late-stage trial. The companies are now engaging with regulatory authorities to pursue approval for the vaccine.
The trial began by enrolling patients with stage IIB to IV melanoma whose tumors had already been surgically removed. Participants were then divided into two groups, with two-thirds receiving a combination therapy consisting of the personalized vaccine alongside Merck's monoclonal antibody treatment Keytruda. The remaining third received Keytruda as a standard treatment alone.
Merck and Moderna initially confirmed the trial was successful in August but withheld specific data pending a scientific conference. The findings were scheduled to be presented on Saturday at the European Society of Medical Oncology meeting in Madrid. However, following early reports from an oncology news site that broke the embargo, the companies opted to release the top-line results immediately.
The full dataset from the study has been accepted for publication in the New England Journal of Medicine. This release marks the first time detailed outcomes regarding the trial's efficacy have been made public.
The announcement has been framed as a significant step for the potential of mRNA technology in oncology. Stéphane Bancel, the CEO of Moderna, stated that from the beginning the company believed mRNA could create cancer treatments uniquely matched to each patient's tumor. He described the results as a defining moment for that vision, noting they reinforce the conviction that mRNA has the potential to fundamentally change cancer treatment.
The trial data supports the development of individualized medicines designed to target specific tumor characteristics. With the results now public, the focus shifts to the regulatory process as the partners work toward securing authorization for the therapy.
Digital Newz Hub will continue to monitor the regulatory timeline and the upcoming publication of the full study results.
